Colling Kristin P, Banton Kaysie L, Beilman Greg J
Department of Surgery, Division of Critical Care and Acute Care Surgery, University of Minnesota , Minneapolis Minnesota.
Surg Infect (Larchmt). 2018 Feb/Mar;19(2):202-207. doi: 10.1089/sur.2017.255. Epub 2018 Jan 16.
Sepsis accounts for 10% of intensive care unit admissions and significant healthcare costs. Although the mortality rate from sepsis has been decreasing with better critical care, early identification of septic patients, and prompt interventions, the mortality rate remains 20%-30%.
Review of the English-language literature.
Norepinephrine is the first-line vasopressor in shock and is associated with a lower mortality rate as well as fewer adverse effects. Dopamine has similar actions but is associated with significantly more tachydysrhythmias and should be reserved for patients with bradycardia. Epinephrine and vasopressin are appropriate second-line vasopressors and may enable use of lower doses of norepinephrine while improving hemodynamics. Inotropes may be added in patients with cardiac dysfunction.
Appropriate treatment of sepsis includes prompt identification, early antimicrobial drug therapy, appropriate fluid resuscitation, and initiation of vasopressors in the presence of continued septic shock. Further research needs to be done to better understand the ideal timing of the addition of a second agent and the optimal combinations of vasopressors for individual patients.
脓毒症占重症监护病房收治病例的10%,并产生巨大的医疗费用。尽管随着重症监护水平的提高、脓毒症患者的早期识别及及时干预,脓毒症的死亡率一直在下降,但死亡率仍为20% - 30%。
回顾英文文献。
去甲肾上腺素是休克治疗的一线血管活性药物,其死亡率较低且不良反应较少。多巴胺有类似作用,但会显著增加快速性心律失常的发生,应仅用于心动过缓患者。肾上腺素和血管加压素是合适的二线血管活性药物,可在改善血流动力学的同时减少去甲肾上腺素的用量。对于心功能不全患者,可加用正性肌力药物。
脓毒症的恰当治疗包括及时识别、早期抗菌药物治疗、适当的液体复苏以及在持续性脓毒症休克时启动血管活性药物治疗。需要进一步研究以更好地了解加用第二种药物的理想时机以及针对个体患者的血管活性药物最佳组合。